Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

17.68 -1.65 (-8.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 980,201
Open 19.17
Bid (Size) 17.68 (500)
Ask (Size) 17.90 (200)
Prev. Close 19.33
Today's Range 17.60 - 19.33
52wk Range 12.12 - 35.34
Shares Outstanding 41,833,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations. 
Via The Motley Fool

Performance

YTD
+29.5%
+29.5%
1 Month
+7.0%
+7.0%
3 Month
+29.4%
+29.4%
6 Month
+26.8%
+26.8%
1 Year
-27.3%
-27.3%

More News

Read More
News headline image
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗
Via The Motley Fool
Topics Artificial Intelligence
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗
Via Stocktwits
News headline image
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
From Janux Therapeutics
Via Business Wire
News headline image
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Which stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-12-02: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
Via Stocktwits
News headline image
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux (JANX) R&D Soars Revenue Misses ↗
Via The Motley Fool

Frequently Asked Questions

Is Janux Therapeutics, Inc. - Common Stock publicly traded?
Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Janux Therapeutics, Inc. - Common Stock trade on?
Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?
The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market
What is the current price of Janux Therapeutics, Inc. - Common Stock?
The current price of Janux Therapeutics, Inc. - Common Stock is 17.68
When was Janux Therapeutics, Inc. - Common Stock last traded?
The last trade of Janux Therapeutics, Inc. - Common Stock was at 09/10/26 04:00 PM ET
What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?
The market capitalization of Janux Therapeutics, Inc. - Common Stock is 739.61M
How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?
Janux Therapeutics, Inc. - Common Stock has 740M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.